Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945064 | 0.81 | GRM2 (0.45) | FYNGRM2HSP90AB1ACHEKDM4E | |
| SCHEMBL5951471 | 0.72 | GRM2 (0.40) | FYNGRM2HSP90AB1 | |
| SCHEMBL4941945 | 0.71 | GRM2 (0.44) | GRM2ACHEALDH1A1MAPTESR1 | |
| SCHEMBL11600975 | 0.68 | MEN1 (0.40) | FYNGRM2HSP90AB1ACHEKDM4E | |
| SCHEMBL10493480 | 0.67 | GRM2 (0.53) | GRM2ACHE | |
| SCHEMBL11130766 | 0.65 | GRM2 (0.34) | GRM2HSP90AB1 | |
| SCHEMBL5951189 | 0.65 | HSP90AB1 (0.39) | GRM2HSP90AB1ACHE | |
| SCHEMBL5952581 | 0.65 | GRM2 (0.41) | GRM2HSP90AB1ACHE | |
| SCHEMBL11117547 | 0.65 | GRM2 (0.56) | GRM2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL11116530 | 0.64 | GRM2 (0.41) | GRM2KDM4EMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096935-A1 | Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| EP-1807073-A2 | HETEROCYCLIC INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006047237-A2 | HETEROCYCLIC INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096935-A1 | Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRIK2, GRM1 | FYN 2409/4885GRM2 1/4885HSP90AB1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.